Pfizer’s breast cancer therapy Palbociclib, better known as Ibrance, is likely to receive insurance coverage.
The Pharmaceutical Benefits Committee of Health Insurance Review & Assessment Service (HIRA)건강보험심사평가원 Thursday concluded the Ibrance Cap is appropriate to receive insurance benefits.
If Palbociclib passes a drug price negotiation between the pharmaceutical company and National Health Insurance Service(NHIS)국민건강보험공단, it can get insurance coverage when people take the drug with Letrozole (a product name: Femara Tab.) as the first endocrine therapy.
Before announcing the result of the assessment, a group of breast cancer patients has called for the government and Pfizer to provide insurance benefits for Palbociclib.
The committee also made a similar judgment for melanoma treatment Mekinist Tab. made by Novartis when taken together with Dabrafenib (a product name: Tafinlar Cap).
Meanwhile, lung cancer therapy made by Roche Korea한국로슈, Alecensa (compound: alectinib), diabetics therapy made by Novo Nordisk Pharma노보노디스크, Victoza Pen Inj, and hepatitis B treatment made by Ildong Pharmaceutical일동제약, Besivo Tab., received conditional insurance coverage.
The committee evaluated six substances submitted by five pharmaceutical companies.
<© Korea Biomedical Review, All rights reserved.>